3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Ovarian Neoplasms
10
Neoplasms
3
Fallopian Tube Neoplasms
3
Breast Neoplasms
3
Prostatic Neoplasms
2
Neoplasm Metastasis
2
Brain Neoplasms
2
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
SCLC,Extensive Stage
1
Rare Tumor
1
Penile Neoplasms
1
Pathologic Complete Response
1
Pancreatic Adenocarcinoma Metastatic
1
Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma
1
Ovarian Carcinosarcoma
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Hemangiosarcoma
1
Glioblastoma
1
Endometrial Neoplasms
1
Cystadenocarcinoma, Serous
1
Carcinoma, Ovarian Epithelial
1
Carcinoma
1
Biliary Tract Neoplasms
1
Advanced Solid Tumor
1
Interventions
pembrolizumab
61
Cisplatin
37
Carboplatin
23
Radiotherapy
21
Cetuximab
19
Magnetic Resonance Spectroscopy
18
Paclitaxel
17
Specimen Handling
13
Docetaxel
12
Fluorouracil
11
Nivolumab
10
tislelizumab
9
Surgical Procedures, Operative
8
Radiotherapy, Intensity-Modulated
7
Radiation
7
cemiplimab
6
Standard of Care
6
Platinum
6
Chemoradiotherapy
6
Biopsy
6
1,2-diaminocyclohexaneplatinum II citrate
6
toripalimab
5
Drug Therapy
5
130-nm albumin-bound paclitaxel
5
atezolizumab
4
Taxes
4
Ipilimumab
4
Immunotherapy
4
Fluorodeoxyglucose F18
4
Cyclophosphamide
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Squamous Cell Carcinoma of Head and Neck
×
niraparib
×
Clear all
NCT04681469
2022-08-04
PRIME
Gruppo Oncologico del Nord-Ovest
Phase 2
Recruiting
49 enrolled